SEC Comment Letter 0000000000-25-011903 to Journey Medical Corp (DERM)
Journey Medical Corp
Date: Dec. 30, 2025 · CIK: 0001867066 · Accession: 0000000000-25-011903
AI Filing Summary & Sentiment
Letter
December 30, 2025 Claude Maraoui Chief Executive Officer, President and Director Journey Medical Corporation 9237 E Via de Ventura Blvd., Suite 105 Scottsdale, AZ 85258 Re:Journey Medical Corporation Draft Registration Statement on Form S-3 Submitted December 30, 2025 CIK No. 0001867066 Dear Claude Maraoui: This is to advise you that we do not intend to review your registration statement. We request that you publicly file your registration statement and non-public draft submission on EDGAR at least two business days prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Daniel Crawford at 202-551-7767 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:David S. Wolpa, Esq.
Show Raw Text
December 30, 2025
Claude Maraoui
Chief Executive Officer, President and Director
Journey Medical Corporation
9237 E Via de Ventura Blvd., Suite 105
Scottsdale, AZ 85258
Re:Journey Medical Corporation
Draft Registration Statement on Form S-3
Submitted December 30, 2025
CIK No. 0001867066
Dear Claude Maraoui:
This is to advise you that we do not intend to review your registration statement.
We request that you publicly file your registration statement and non-public draft
submission on EDGAR at least two business days prior to the requested effective date and
time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Daniel Crawford at 202-551-7767 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:David S. Wolpa, Esq.